Research Article

Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases

John F. Tierney, Jennifer Poirier, Sitaram Chivukula, Sam G. Pappas, Martin Hertl, Erik Schadde, and Xavier Keutgen

1Division of Surgical Oncology, Department of Surgery, Rush University Medical Center, Chicago, IL, USA
2Division of Transplant, Department of Surgery, Rush University Medical Center, Chicago, IL, USA
3Cantonal Hospital Winterthur, Department of Surgery, Winterthur, Zurich, Switzerland
4University of Zurich, Institute of Physiology, Zurich, Switzerland
5Division of General Surgery, Department of Surgery, The University of Chicago Medical Center, Chicago, IL, USA

Correspondence should be addressed to Xavier Keutgen; xkeutgen@surgery.bsd.uchicago.edu

Received 15 December 2018; Revised 21 January 2019; Accepted 5 February 2019; Published 12 March 2019

1. Introduction

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) were initially thought to be small indolent tumors, when first described 100 years ago, but are now recognized to have malignant potential, with 40-50% of patients developing distant metastases [1]. The presence of metastatic disease is strongly associated with survival for GEP-NETs [2]. The liver is the most common metastatic site for these tumors, and 80% of patients eventually succumb to liver failure due to metastatic tumors [3].

Neuroendocrine tumors (NETs) are one of the few tumor types in which debulking surgery—most commonly performed to remove tumor from the liver—is a recommended treatment for metastatic disease [4, 5]. Current European Neuroendocrine Tumor Society (ENETS) guidelines recommend resection of liver metastases from well- or moderately differentiated GEP-NETs if surgery removes at least 90% of the tumor burden, and some centers in the United States have further lowered the threshold for debulking surgery to 70% with similar outcomes [1, 6].

Although the association of liver metastases with mortality in patients with GEP-NETs is well-established, it is unknown whether primary tumor site is associated with prognosis among patients with neuroendocrine liver metastases (NELM). Additionally, it remains controversial if patients with both hepatic and extrahepatic metastases benefit from operative management, as is the case in the carefully
selected patient with colorectal liver metastases [7]. We therefore used the National Cancer Database (NCDB) to examine survival in patients with grade 1 and 2 GEP-NETs and NELM to determine whether primary tumor site influences survival and also to examine the survival of GEP-NET patients with extrahepatic metastases with and without surgical resection.

2. Methods

The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. It represents the largest database of cancer patients in the United States, comprising about 70% of all patients newly diagnosed with cancer, and contains information regarding cancer treatments within the first six months of diagnosis [8, 9]. The NCDB and the hospitals participating in the NCDB are the source of the de-identified data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors. This study was exempt from IRB review because the NCDB is a public database that does not contain personally identifiable patient information.

Patients diagnosed with neuroendocrine tumors in the colon, pancreas, rectum, small intestine, and stomach between 2004 and 2014 were identified from the NCDB according to tumor location and histology code. Patients with liver metastases at the time of diagnosis were identified by the “CS_METS_DX_LIVER” variable. Only patients with grade 1 and 2 tumors were included. Grade for gastrointestinal NETs was determined by histology code. The codes 8240 and 8249 (well- or moderately differentiated tumors) were defined as grade 1 or 2 tumors and 8013, 8041, and 8246 (poorly differentiated tumors), as grade 3 tumors, and therefore excluded from this study. Grade for pancreatic NETs was determined by the “GRADE” variable and was classified as grade 1 or 2, grade 3, and missing. Pancreatic NET patients with grade 3 tumor or missing information on grade were excluded.

For the primary objective of determining whether primary tumor site influences survival among patients with NELM, Kaplan-Meier survival curves were created for patients with localized disease and with NELM for each site (colon, pancreas, rectum, small intestine, and stomach) and compared for each (localized and NELM) across sites using the Mantel-Haenszel tests.

The following variables were then examined individually to determine whether they were associated with survival among all patients with NELM: hospital type, age, sex, race, ethnicity, Charlson comorbidity index (CCI), radiation therapy status, chemotherapy status, presence of extrahepatic metastases, and surgical approach. Surgical approaches included primary tumor surgery, distant metastatic site surgery, primary tumor and distant site surgery, and no surgery. Debulking operations were defined as operations on both primary and metastatic sites. Differences in survival curves were compared with the Mantel-Haenszel tests, and p values were adjusted using the Benjamini-Hochberg procedure.

Nested Cox proportional hazard models were created using variables significant on univariable analysis, compared and tested for proportionality. Initial models failed the proportionality assumption, indicating that at least one variable interacted with time; the data were therefore split at 22 months to incorporate this interaction with time, and the subsequent models passed the proportionality assumption. Nested models including the time interaction were subsequently compared using the likelihood ratio tests.

Finally, Kaplan-Meier curves were created comparing patients with and without extrahepatic metastases and surgical to nonsurgical patients. These curves were compared using the Mantel-Haenszel tests.

p values less than or equal to 0.05 were considered significant. All analyses were conducted in R, 3.3.2 [10].

3. Results

2947 patients with NELM were identified from the NCDB and included for analysis in this study.

Survival in patients with NELM differed according to primary tumor site. Median survival for patients with small intestinal primary tumors was not reached; these patients survived significantly longer than patients with any other primary tumor site (p < 0.001). Patients with pancreatic NETs survived a median of 52.0 months, significantly longer than those with rectal NETs, who survived a median of 30.7 months (p = 0.01) (Table 1) (Figure 1(a)). Patients with colonic NETs survived 53.7 months and those with stomach NETs survived 31.4 months, but there were no significant differences in survival between colonic, rectal, and stomach primary tumor sites or between pancreatic NETs and colonic and stomach NETs (p = 0.09-0.70).

In comparison, patients with localized NETs (stage I-III, 47,303 patients identified) had median survivals ≥136 months, regardless of primary tumor site (Figure 1(b)). Patients with rectal NETs survived significantly longer (median not reached) than those with tumors in any other site (p < 0.001), and patients with colonic NETs survived longer (median not reached) than those with pancreatic, small intestinal, or gastric NETs (p < 0.001).

Among all patients with NELM, 644 (21.8%) underwent an operation on both the primary tumor site and a distant metastatic site (debulking), 625 (21.2%) underwent primary tumor resection only, 41 (1.4%) underwent resection of metastases only, and 878 (29.8%) did not have an operation. Debulking operations were associated with prolonged survival on univariable analysis compared to all other groups (median survival not reached; p < 0.001) (Figure 2(a)). Additional factors associated with prolonged survival on univariable analysis included treatment at an academic/research hospital, younger age, lower CCI, absence of chemotherapy, and lack of extrahepatic metastases (Table 2). Debulking operations remained significantly associated with prolonged survival on multivariable analysis (HR 0.23-0.43 when compared to no surgery, p < 0.001). Other significant factors associated with prolonged survival identified on multivariable analysis included treatment at an academic/research hospital when compared to all other hospital types, CCI of 0 when compared to all other CCI scores, absence of extrahepatic metastases, and younger patient age (Table 3).
There were significant differences in survival according to primary tumor site among patients who had operations on both the primary tumor site and a distant metastatic site. Patients with small intestinal NETs who had debulking operations survived significantly longer (median not reached) than patients with either pancreatic NETs (65.1 months) or colonic NETs (44.8 months) \((p < 0.001)\). Patients with pancreatic NETs who underwent debulking operations survived significantly longer than those with colonic NETs \((p < 0.001)\). An insufficient number of patients with gastric or rectal NETs underwent debulking surgery for these patients to be included in the analysis.

Subgroup analysis was performed to evaluate the effect of an operation on survival in NELM patients with extrahepatic metastases. Patients with extrahepatic metastases who underwent any operation survived a median of 38.7 months, shorter than patients with liver metastases alone who underwent an operation (median not reached) but significantly longer than patients with extrahepatic disease who did not have an operation (18.6 months, \(p < 0.001\)) (Figure 2(b)).

### 4. Discussion

In this study, we demonstrated that among GEP-NET patients with NELM, significant differences in survival exist according to primary tumor location.

Not surprisingly, patients with localized (stage I-III) GEP-NETs had excellent long-term survival, with median survival times greater than 136 months, consistent with the data from a recent study using the SEER database [11]. Similar to that study, we demonstrated that patients with localized rectal NETs have the longest overall survival (median not reached). The SEER study, which had longer follow-up, found that patients with localized pancreatic NETs had the lowest 20-year survival, which was not replicated in the data presented here. This difference could be related to the shorter follow-up time in the SEER study's use of NET-specific survival, or more likely to the fact that we excluded high-grade NETs [11].

Interestingly, we found that among patients with liver metastases, different primary tumor sites are associated with improved survival. This is the first study to our knowledge that demonstrated that among patients with NELM, those with small intestinal primary tumors have the longest and gastric and rectal NETs have the shortest overall survival. We cannot explain this finding using the data available in the NCDB but suggest that different biological behavior and response to therapies contribute to this observation [12]. Previous studies have demonstrated that small intestinal and pancreatic NETs can be identified by their different genomic profiles, and it is possible that these molecular differences also might affect prognosis [13, 14]. Moreover, response rates of commonly used therapies such as long-acting octreotide analogues also vary according to primary tumor site as demonstrated in previous studies, with pancreatic NETs responding less well to long-acting octreotide than small bowel NETs for example [12, 15]. The difference in prognosis according to primary tumor site seen here also highlights the importance of identifying the location of unknown primary tumors, especially as newer therapies become available [16].

Our secondary objective was to investigate the factors associated with prolonged survival among patients with NELM. In this study, among other factors, debulking operations were associated with prolonged survival, reaffirming the role for an aggressive surgical approach in carefully selected patients with NELM as advocated by many centers [6, 17, 18]. Debulking surgery has been an accepted treatment strategy for stage IV NETs since the 1990s, and the rationale for debulking has evolved from symptom control to prolonging survival over time, but this is the first study using a large national sample to demonstrate a survival benefit for GEP-NET patients with NELM patients who undergo debulking [17, 19]. The precise amount of tumor that should be removed to confer a benefit is controversial, with recommendations ranging from 70% at certain high-volume centers to 90% in the ENETS guidelines [3, 18]. We are unable to comment on a debulking threshold, as the extent of disease or of resection is not reported in the NCDB; prospective studies should be performed to further examine survival after debulking.

The finding that treatment at an academic or research center was independently associated with prolonged survival among all patients with grade 1 or 2 NELM suggests that management of these patients should perhaps be concentrated at high-volume centers, as has been proposed by other authors and in other diseases [20, 21].

Finally, we sought to examine the role of surgical management of patients with extrahepatic metastases. The effect of extrahepatic metastases on survival promises to become a more critical issue for clinicians in determining prognosis and treatment for NELM patients as imaging technologies have improved and \(^{68}\)Gallium DOTATATE PET CT is now used more commonly for staging of NETs. In our center's initial experience with \(^{68}\)Gallium DOTATATE PET CT, new bone metastases were detected in 18% of patients when compared to conventional imaging such as CT and MRI, thereby vastly expanding the number of patients with known extrahepatic disease [22]. It remains unclear, however, whether the presence of extrahepatic metastases should be a contraindication to operative management. Herein, we found that the presence of extrahepatic metastases was associated with reduced survival among all patients with GEP-NETs.
and NELM, but patients with extrahepatic metastases who underwent surgery survived significantly longer than those who did not.

We acknowledge that a selection bias could have affected these findings, as patients who underwent surgery might have had less extensive disease either within or outside the
liver. The prolonged survival demonstrated among patients who had an operation, however, may indicate that operative management of these patients conveys some benefit in a subset of patients. Two previous studies of patients who underwent liver-directed therapy (resection, debulking, and/or ablation) for neuroendocrine metastases at high-volume centers found that although patients with extrahepatic metastases had worse prognoses than patients with liver metastases alone, they still enjoyed a median survival of up to 87 months [23, 24].

We expect that as imaging technology continues to improve, clinicians will face the challenge of treating patients with extrahepatic metastases more frequently. Further prospective studies should be performed to evaluate the role of operative management in these patients.

There are several limitations to this study, in addition to the inherent data entry errors common to all large database studies. First, this study is retrospective and observational, and therefore, is subject to selection bias. The effects of selection bias are particularly important in the interpretation of

Table 2: Factors associated with prolonged survival among patients with neuroendocrine liver metastases on univariate analysis.

| Variable                        | N     | Median survival (months) | 95% CI     | p value |
|---------------------------------|-------|--------------------------|------------|---------|
| Hospital type                   |       |                          |            | <0.001  |
| Community Cancer Program        | 163   | 48.5                     | 37.4 – NR  |         |
| Comprehensive Community Cancer Program | 720   | 57.8                     | 48.8 – 66.9|         |
| Academic/Research Program       | 986   | NR                       | 60.4 – NR  |         |
| Integrated Network Cancer Program | 212   | 48.6                     | 40.3 – 54.7|         |
| Age                             |       |                          |            | <0.001  |
| Age < median (61 years)         | 1157  | NR                       | 65.1 – NR  |         |
| Age ≥ median (61 years)         | 1031  | 44.4                     | 38.6 – 52.0|         |
| Gender                          |       |                          |            | 0.99    |
| Female                          | 1034  | 62.6                     | 54.8 – NR  |         |
| Male                            | 1154  | 60.4                     | 54.9 – NR  |         |
| Race                            |       |                          |            | 0.23    |
| Asian or Pacific Islander       | 34    | NR                       | NR – NR    |         |
| Black                           | 313   | 65.1                     | 62.6 – NR  |         |
| Other or unknown                | 48    | NR                       | 35.6 – NR  |         |
| White                           | 1793  | 60.2                     | 54.9 – NR  |         |
| Hispanic                        |       |                          |            | 0.99    |
| Hispanic                        | 88    | NR                       | 52.1 – NR  |         |
| Non-Spanish; non-Hispanic       | 2013  | 60.4                     | 56.0 – NR  |         |
| Unknown                         | 87    | NR                       | 38.2 – NR  |         |
| Charlson comorbidity index      |       |                          |            | <0.001  |
| Charlson 0 or none              | 1666  | 60.4                     | 56.7 – NR  |         |
| Charlson 1                      | 388   | NR                       | 44.1 – NR  |         |
| Charlson 2 or more              | 134   | 41.9                     | 24.4 – NR  |         |
| Radiation therapy               |       |                          |            | 0.36    |
| No radiation therapy            | 2016  | 62.6                     | 56.7 – NR  |         |
| Radiation therapy               | 142   | 49.8                     | 37.1 – NR  |         |
| Chemotherapy                    |       |                          |            | <0.001  |
| Chemotherapy                    | 543   | 46.5                     | 35.8 – 54.9|         |
| No chemotherapy                 | 1525  | 66.9                     | 60.2 – NR  |         |
| Extrahepatic metastatic sites   |       |                          |            | <0.001  |
| No extrahepatic metastatic sites| 2026  | 65.1                     | 60.4 – NR  |         |
| Extrahepatic metastatic sites   | 162   | 22.4                     | 17.0 – 29.8|         |
| Surgery                         |       |                          |            | <0.001  |
| No surgery                      | 878   | 33.0                     | 29.1 – 37.4|         |
| Distant site surgery only       | 41    | 33.2                     | 21.9 – 66.9|         |
| Primary site surgery only       | 625   | NR                       | 60.4 – NR  |         |
| Primary and distant site surgery| 644   | NR                       | 65.1 – NR  |         |
the findings that debulking is associated with prolonged survival among all NELM patients and that surgery is associated with prolonged survival among patients with both hepatic and extrahepatic metastases, as discussed above. It is possible that a variable that is unable to be assessed in the NCDB, such as tumor burden or extent of tumor removal during surgery, is responsible for the differences in survival reported here. Operations on the primary and metastatic site, which were classified as debulking operations, could include anything from a liver biopsy to a radical resection of all metastatic foci. The survival benefits described here, however, confirm the experience of high-volume centers described in larger retrospective cohorts, which suggests that optimal management of NELM should, in well-selected patients, include debulking and consideration of surgery in patients with extrahepatic metastases. Second, the NCDB only includes treatment information within the first six months of diagnosis, and does not provide information regarding the type (e.g., long-acting octreotide analogues) or use of specific preoperative, nonoperative, or adjuvant management, which improve outcome [25, 26]. Third, a large amount of patients listed in the NCDB with distant metastases at the time of diagnosis did not have a specific metastatic site listed, and it is likely that some of these patients had liver metastases but were excluded from the study.

Despite these limitations, we have shown that among GEP-NET patients with NELM, those with small intestinal primary tumors have the best overall prognosis that debulking is associated with prolonged survival in these patients and that a subset of patients with extrahepatic metastases might also potentially benefit from operative management.

Data Availability

The data used for this study was obtained from the National Cancer Database. It may be requested from the National Cancer Database during the biannual Participant User Files application period.

Additional Points

Synopsis. Patients with small intestinal primary NETs have the best prognosis of all patients with neuroendocrine liver metastases. Debulking operations are associated with prolonged survival for all GEP NET patients.

Disclosure

This study was presented as a poster at the annual meeting of the American Association of Endocrine Surgeons, Durham, NC, May 6-8, 2018.

Conflicts of Interest

The authors declare that they have no conflicts of interest.
References

[1] M. Pavel, D. O’Toole, F. Costa et al., "ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site," Neuroendocrinology, vol. 103, no. 2, pp. 172–185, 2016.

[2] J. C. Yao, M. Hassan, A. Phan et al., "One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States," Journal of Clinical Oncology, vol. 26, no. 18, pp. 3063–3072, 2008.

[3] B. Givi, S. E. J. Pommier, A. K. Thompson, B. S. Diggins, and R. F. Pommier, "Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival," Surgery, vol. 140, no. 6, pp. 891–898, 2006.

[4] J. M. Sarmiento, G. Heywood, J. Rubin, D. M. Istrup, D. M. Nagorney, and F. G. Que, "Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival," Journal of the American College of Surgeons, vol. 197, no. 1, pp. 29–37, 2003.

[5] F. Bagante, G. Spolverato, K. Merath et al., "Neuroendocrine liver metastasis: the chance to be cured after liver surgery," Journal of Surgical Oncology, vol. 115, no. 6, pp. 687–695, 2017.

[6] A. N. Graff-Baker, D. A. Sauer, S. E. J. Pommier, and R. F. Pommier, "Expanded criteria for carcinoid liver debulking: maintaining survival and increasing the number of eligible patients," Surgery, vol. 156, no. 6, pp. 1369–1377, 2014.

[7] U. Leung, M. Gönen, P. J. Allen et al., "Colorectal cancer liver metastases and concurrent extrahepatic disease treated with resection," Annals of Surgery, vol. 265, no. 1, pp. 158–165, 2017.

[8] American College of Surgeons, "About the National Cancer Database," November 2017, https://www.facs.org/quality-programs/cancer/ncdb/about.

[9] R. P. Merkow, A. W. Rademaker, and K. Y. Bilimoria, "Practical guide to surgical data sets: National Cancer Database (NCDB)," JAMA Surgery, vol. 153, no. 9, pp. 850-851, 2018.

[10] R Core Team, "R Foundation for Statistical Computing, Vienna, Austria," 2016, https://www.R-project.org/.

[11] W. Chi, R. R. P. Warner, D. L. Chan et al., "Long-term outcomes of gastroenteropancreatic neuroendocrine tumors," Pancreas, vol. 47, no. 3, pp. 321–325, 2018.

[12] M. E. Caplin, M. Pavel, J. B. Cwikla et al., "Lanreotide in metastatic enteropancreatic neuroendocrine tumors," The New England Journal of Medicine, vol. 371, no. 3, pp. 224–233, 2014.

[13] J. C. Carr, E. A. Boese, P. M. Spanheimer et al., "Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling," Surgery, vol. 152, no. 6, pp. 998–1007, 2012.

[14] S. K. Sherman, J. E. Maxwell, J. C. Carr et al., "Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors," Clinical & Experimental Metastasis, vol. 31, no. 8, pp. 935–944, 2014.

[15] A. Rinke, H.-H. Müller, C. Schade-Brittinger et al., "Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group," Journal of Clinical Oncology, vol. 27, no. 28, pp. 4656–4663, 2009.

[16] K. P. Massimino, E. Han, D. E. J. Pommier, and R. F. Pommier, "Laparoscopic surgical exploration is an effective strategy for locating occult primary neuroendocrine tumors," American Journal of Surgery, vol. 203, no. 5, pp. 628–631, 2012.

[17] H. A. Farley and R. F. Pommier, "Treatment of neuroendocrine liver metastases," Surgical Oncology Clinics of North America, vol. 25, no. 1, pp. 217–225, 2016.

[18] J. E. Maxwell, S. K. Sherman, T. M. O’Dorisio, A. M. Bellizzi, and J. R. Howe, "Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy?", Surgery, vol. 159, no. 1, pp. 320–335, 2016.

[19] G. P. McEntee, D. M. Nagorney, L. K. Kvols, C. G. Moertel, and C. S. Grant, "Cytoxic reductive hepatic surgery for neuroendocrine tumors," Surgery, vol. 108, no. 6, pp. 1091–1096, 1990.

[20] D. C. Metz, J. Choi, J. Strosberg et al., "A rationale for multidisciplinary care in treating neuroendocrine tumours," Current Opinion in Endocrinology & Diabetes and Obesity, vol. 19, no. 4, pp. 306–313, 2012.

[21] M. E. Lidsky, Z. Sun, D. P. Nussbaum, M. A. Adam, P. J. Speicher, and D. G. Blazer III, "Going the extra mile: improved survival for pancreatic cancer patients traveling to high-volume centers," Annals of Surgery, vol. 266, no. 2, pp. 333–338, 2017.

[22] J. F. Tierney, C. Kosche, E. Schadde et al., "68Gallium-DOTA-TATE positron emission tomography–computed tomography (PET CT) changes management in a majority of patients with neuroendocrine tumors," Surgery, vol. 165, no. 1, pp. 178–185, 2019.

[23] G. Spolverato, F. Bagante, L. Aldrighetti et al., "Neuroendocrine liver metastasis: prognostic implications of primary tumor site on patients undergoing curative intent liver surgery," Journal of Gastrointestinal Surgery, vol. 21, no. 12, pp. 2039–2047, 2017.

[24] A. Ejaz, B. N. Reames, S. Maithel et al., "The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis," Journal of Surgical Oncology, vol. 116, no. 7, pp. 841–847, 2017.

[25] P. J. Mazzaglia, E. Berber, S. E. J. Pommier, and R. F. Pommier, "Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival," Surgery, vol. 142, no. 1, pp. 10–19, 2007.

[26] M. Fairweather, R. Swanson, J. Wang et al., "Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database," Annals of Surgical Oncology, vol. 24, no. 8, pp. 2319–2325, 2017.